Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1

Cancer Biology and Therapy

Volumn 3, Issue 4, 2004, Pages 402-405

  Niu, Qi ^a   Perruzzi, Carole ^a   Voskas, Daniel ^b   Lawler, Jack ^a   Dumont, Daniel J ^b   Benjamin, Laura E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Akt; Apoptosis; Endothelial cell; Tie 2; TSP 1

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RNA; THROMBOSPONDIN 1; AKT1 PROTEIN, HUMAN; ANGIOGENESIS INHIBITOR; ONCOPROTEIN; PRIMER DNA; PROTEIN SERINE THREONINE KINASE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL VIABILITY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; TUMOR GROWTH; BIOSYNTHESIS; CELL SURVIVAL; CULTURE TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; DNA PRIMERS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1;

EID: 7244253411     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.4.735     Document Type: Article

References (37)

1. Hanahan D, J Folkman. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64.
2. Folkman J, What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
3. Risau W, Mechanisms of angiogenesis. Nature 1997; 386(6626):671-4.
4. Shalaby F, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376:62-6.
5. Fong GH, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376:66-70.
6. Sato TN, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376:70-4.
7. Puri MC, et al. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 1995; 14:5884-91.
8. Dumont DJ, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994; 8:1897-909.
9. Valenzuela DM, et al. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 1999; 96:1904-9.
10. Hawighorst T, et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 2002; 160:1381-92.
11. Maisonpierre PC, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [see comments]. Science 1997; 277:55-60.
12. Ward NL, DJ Dumont, The angiopoietins and Tie2/Tek: Adding to the complexity of cardiovascular development. Semin Cell Dev Biol 2002; 13:19-27.
13. Jones N, et al. Rescue of the early vascular defects in Tek/Tie2 null mice reveals an essential survival function. EMBO Rep 2001; 2:438-45.
14. Holash J, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284:1994-8.
15. Adini A, et al. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 2002; 62:2749-52.
16. Benjamin LE, E Keshet. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997; 94:8761-6.
17. Holash J, SJ Wiegand, GD Yancopoulos. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18:5356-62.
18. Lin P, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 1998; 95:8829-34.
19. Liu W, et al. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 2000; 5:323-8.
20. Timothy R, Carlson YF, Peter C. Maisonpierre, Milan Mrksich§, and Alex O. Morla, Direct Cell Adhesion to the Angiopoietins Mediated by Integrins. J Biol Chem 2001; 276:26516-25.
21. Arnold LD, et al. Molecular Interactions in Crystal Structures of Potent Inhibitors Bound to the Kinase Domain of Tie-2. 93rd Annual Meeting of the American Association for Cancer Research 2002; 848.
22. Qian, XD, et al. Antiangiogenic activities of BSF 466895 (A-422885.66), a potent and selective low molecular weight Tie-2 kinase inhibitor. 2nd International Symposium of the German Priority Research Program SPP1069 2002; Kloster Seeon, Germany.
23. Wishart N, et al. Structural activity relationships for a novel series of pyrrolo[2,3-d]pyrimidine Tie-2 inhibitors. 93rd Annual Meeting of the American Association for Cancer Research 2002; 848-9.
24. Lawler J, Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002; 6:1-12.
25. Nor JE, et al. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 2000; 37:209-18.
26. Richard L, Velasco P, Detmar M. A simple immunomagnetic protocol for the selective isolation and long-term culture of huaman dermal microvascular endothelial cells. Exp Cell Res 1998; 240:1-6.
27. Voorhoeve PM, R Agami. Knockdown stands up. Trends Biotechnol 2003; 21(1):2-4.
28. Lawler J, et al The structure of human platelet thrombospondin. J Biol Chem 1985; 260:3762-72.
29. Miao WM, et al. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res 2001; 61:7830-9.
30. Guo N, et al. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997; 57:1735-42.
31. Rice AJ, MA Steward, CM Quinn. Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast. J Clin Pathol 2002; 55:921-5.
32. Tobita K, et al. Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int J Oncol 2002; 21:1189-95.
33. Yamaguchi M, et al. Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with nonsmall cell lung cancer. Lung Cancer 2002; 36:143-50.
34. Lawler J. The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 2000; 12:634-40.
35. Adams JC. Thrombospondins: Multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 2001; 17:25-51.
36. Streit M, et al. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res 2002; 62:2004-12.
37. Tomii Y, et al. Human thrombospondin 2 inhibits proliferation of microvascular endothe-lial cells. Int J Oncol 2002; 20:339-42.